Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.
about
Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease.Lipid metabolism emerges as a promising target for malignant glioma therapy.Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration.MicroRNAs: a connection between cholesterol metabolism and neurodegeneration.Ligands of Therapeutic Utility for the Liver X Receptors.Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatmentLiver X receptor-β improves autism symptoms via downregulation of β-amyloid expression in cortical neuronsRole of ATP-binding cassette transporters in brain lipid transport and neurological disease.Distinguishing Lewy body dementias from Alzheimer's disease.Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairmentMemory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomersPharmacotherapeutic targets in Alzheimer's diseaseSterol regulation of metabolism, homeostasis, and development.Liver X receptor modulators: a review of recently patented compounds (2007 - 2009).Common Pesticide, Dichlorodiphenyltrichloroethane (DDT), Increases Amyloid-β Levels by Impairing the Function of ABCA1 and IDE: Implication for Alzheimer's Disease.Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist.MiR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression.Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants.A novel enzyme immunoassay specific for ABCA1 protein quantification in human tissues and cells.Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier.
P2860
Q29013008-B8BBECE2-9D9D-466F-BAE9-56951821DF51Q30493684-43EF18CC-0B7C-4555-8070-76CB75428638Q30684049-B8B9EF7C-29F2-4C24-8A53-5DEFED90A384Q33906674-B8AE3665-972C-4BEB-ACDA-DE60CF628872Q34518507-A82477E7-E931-4689-BCDF-E8592F71CED9Q34613640-6E29DD2A-4AAD-4B89-9233-E155FA43D76BQ36244293-CB9181DD-4C3E-40C1-9575-323A0FA81005Q36383616-31DCC26E-2CE2-450B-8793-6F9227FBE315Q36407043-44B1B610-DDB4-4015-9B8E-308442786F29Q36879758-9E6F1446-DFB4-4E65-ACF3-463E2F66DBF8Q36987318-8E3899F9-C0DE-4A56-9EEA-4B749BE642FBQ36998833-8688129C-CDB2-4579-A274-E24071A6B350Q37141691-AAE62E68-A2E4-4617-B346-96C8802C0D2CQ37225388-A18F34E8-56B0-4E28-ADFE-47B462711018Q37295067-6A538763-FCA8-43F5-B3FF-B2423F01D5D4Q37569266-8535106D-071D-4C3F-B259-158AC8D2A59CQ37714905-71F46DBF-FC22-48E4-AF5E-F085DAE65E5CQ38905832-7D6A2659-D525-4257-8A34-117315ABB52DQ39495324-40BF12E1-8D24-49CC-9A1D-20428ADCDE58Q42156626-AC7A0292-684D-4E3E-9F27-87D8E3F5E8F1Q46034429-0B017A16-4A5D-419D-AB77-8C007E08E75FQ46549250-54B429D8-7650-4E66-9343-816431124DF0Q52148894-156709DE-522F-4566-8861-20491FC43591
P2860
Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Role of LXR and ABCA1 in the p ...... or a new therapeutic approach.
@en
type
label
Role of LXR and ABCA1 in the p ...... or a new therapeutic approach.
@en
prefLabel
Role of LXR and ABCA1 in the p ...... or a new therapeutic approach.
@en
P1476
Role of LXR and ABCA1 in the p ...... for a new therapeutic approach
@en
P2093
Iliya Lefterov
P304
P356
10.2174/156720507780362227
P577
2007-04-01T00:00:00Z